PULSE Challenge: From Serendipity to Design Principles Molecular Glues as a Prelude to RIPTACs
February 9, 2026 @ 15:00 – 16:00 CET
Traditionally viewed as inhibitors, small molecules have evolved through the discovery of molecular glues—compounds that create function by stabilizing protein-protein interactions. This shift from serendipitous discovery to “induced proximity” has expanded the druggable proteome and redefined how we control cellular behavior.
The first half of this talk traces the evolution of molecular glues, framing them as versatile proximity-inducing agents rather than just degradation tools. We emphasize their impact on our understanding of protein surfaces and cellular organization.
The second half introduces Regulated Induced Proximity Targeting Chimeras (RIPTACs). We highlight HLD-0915, a novel RIPTAC targeting prostate cancer. In preclinical models, HLD-0915 demonstrated tumor regression and a favorable therapeutic index, even in drug-resistant cases. Finally, we present Phase 1 data from mCRPC patients, showing strong tolerability and encouraging anti-tumor activity in heavily pretreated populations.
Host: Vasanthanathan Poongavanam
Moderator: Per Arvidsson
The seminar series PULSE Challenge is connected to the MSCA co-funded* postdoctoral program SciLifeLab PULSE, that will train 48 future leaders in life sciences. The program focuses on innovative, fundamental and translational research carried out in supportive and diverse academic and industrial environments, preparing postdocs with necessary skills for long-term career sustainability. Click HERE to find out more about SciLifeLab PULSE
On-line event via Zoom
Presenters:
Dr. Muthukumaran Venkatachalapathy
Biography:
Dr. Muthukumaran Venkatachalapathy is currently an Associate Research Scientist in the Department of Chemistry at Yale University (with Professor Craig Crews and Prof David Spiegel). With a strong background in Chemical Biology, he earned his Ph.D. from the Max Planck Institute in Dortmund, Germany. His research interests focus on developing novel chemical biology modalities for targeted protein degradation and therapeutic discovery
Dr. Nilesh Zaware
Biography:
Dr. Nilesh Zaware currently serves as the Associate Director of Clinical Operations at Halda Therapeutics (USA). He holds a Ph.D. in Medicinal Chemistry from Duquesne University in Pittsburgh. Following his doctoral studies, he completed postdoctoral training at the University of Pittsburgh and Duquesne University. Previously, he served as a Research Assistant Professor at the Icahn School of Medicine at Mount Sinai. His expertise spans small-molecule and heterobifunctional drug discovery through the oversight of oncology clinical trials.
Google Calendar 
